Metagenomi, Inc. Common Stock (MGX) Revenue Quarterly: History & Chart

Metagenomi, Inc. Common Stock(MGX)

Biotechnology · Emeryville, CA

$1.05+0.01 (+0.96%)

Delayed quote: Oct 6, 2026, 1:24 PM EDT

About Metagenomi, Inc. Common Stock

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Emeryville, CA

113 employees

www.metagenomi.co

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jian Irish

View full financials

Quarterly Revenue

Basis: latest reported fiscal quarter (Q2 FY2026). Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly revenue is ($257,000). Quarterly revenue is the total sales generated during the latest fiscal quarter.

Revenue TTM|Revenue Annual|Revenue CAGR|Financials

Quarterly Revenue

MGX Quarterly Revenue

$-257000.00

Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $-257000.00.

-107.68% over 10Y

MGX P/S Ratio

Full P/S Ratio page

P/S Ratio

MGX P/S Ratio Chart

2.91

FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:27:27.185Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

MGX EV/Sales

Full EV/Sales page

EV/Sales

MGX EV/Sales Chart

2.82x

Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T17:27:27.185Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Revenue History

Period	Quarterly Revenue	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	($257,000)	N/A	N/A
Q1 FY2026Period end 2026-03-31	$1.25M	(68.09%)	(69.76%)
Q4 FY2025Period end 2025-12-31	$3.91M	(54.83%)	(59.32%)
Q3 FY2025Period end 2025-09-30	$8.66M	+1.72%	(24.80%)
Q2 FY2025Period end 2025-06-30	$8.51M	+106.28%	(57.45%)
Q1 FY2025Period end 2025-03-31	$4.13M	(57.07%)	(63.02%)
Q4 FY2024Period end 2024-12-31	$9.61M	(16.50%)	(22.46%)
Q3 FY2024Period end 2024-09-30	$11.51M	(42.45%)	(6.87%)
Q2 FY2024Period end 2024-06-30	$20.01M	+79.30%	+76.48%
Q1 FY2024Period end 2024-03-31	$11.16M	(10.00%)	+28.90%
Q4 FY2023Period end 2023-12-31	$12.40M	+0.29%	+121.61%
Q3 FY2023Period end 2023-09-30	$12.36M	+9.05%	+151.64%
Q2 FY2023Period end 2023-06-30	$11.34M	+30.96%	+238.82%
Q1 FY2023Period end 2023-03-31	$8.66M	+54.73%	+158.73%
Q4 FY2022Period end 2022-12-31	$5.59M	+13.88%	N/A
Q3 FY2022Period end 2022-09-30	$4.91M	+46.83%	N/A
Q2 FY2022Period end 2022-06-30	$3.35M	+0.00%	N/A
Q1 FY2022Period end 2022-03-31	$3.35M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.